Key Highlights

  • Shares were down 18.63% to USD 5.24 in pre-market trading on November 3, 2026.
  • Third quarter 2026 Revenue was USD 110.0 million, down 52% from USD 231.1 million.
  • The net loss was USD 32.7 million, or USD 0.64 per diluted share.
  • 2026 revenue guidance was cut to USD 600 million to USD 645 million.
  • Naloxone product sales fell 42% to USD 43.5 million.

Pre-Market Selling After the Earnings Release (down USD 1.20, 18.63%)

Emergent BioSolutions (NYSE:EBS) was down 18.63% to USD 5.24 in pre-market trading on November 3, 2026, measured against the Monday close. The move follows the third quarter results the company released on November 2, 2026, which showed a steep revenue decline and a lower full-year outlook.

Inside the Quarterly Results

According to a company press release dated November 2, 2026, total revenue for the quarter ended September 30, 2026 was USD 110.0 million, compared with USD 231.1 million a year earlier. The company reported a net loss of USD 32.7 million against Net Income of USD 51.2 million in the prior-year quarter. Adjusted EBITDA was a loss of USD 4.6 million, compared with a profit of USD 92.6 million.

Naloxone sales, covering NARCAN and KLOXXADO, were USD 43.5 million, down from USD 74.9 million, mainly on lower U.S. over-the-counter NARCAN sales. Smallpox countermeasure sales fell to USD 26.7 million from USD 83.6 million, which the company attributed mainly to U.S. government timing. Anthrax countermeasure sales rose to USD 25.1 million from USD 1.4 million on higher CYFENDUS sales.

Guidance and Company Background

Emergent, based in Gaithersburg, Maryland, focuses on biodefense medical countermeasures and a naloxone portfolio. The company lowered 2026 revenue guidance to USD 600 million to USD 645 million from USD 645 million to USD 675 million. Adjusted EBITDA guidance fell to USD 110 million to USD 140 million from USD 130 million to USD 150 million. Adjusted gross Margin guidance was raised to 45% to 47%.

The company also said its chief financial officer will retire effective December 31, 2026, with the treasurer becoming interim chief financial officer on January 1, 2027. It described a multi-year transformation with priorities that include reducing debt.

Balance Sheet and Risks

The release did not disclose cash or total Debt balances, but said the company completed the repurchase of USD 75 million in aggregate principal of its senior unsecured notes. Interest expense is assumed at about USD 38 million for 2026.

Shares can move sharply on thin pre-market volume. Revenue from government contracts can vary with order timing, and over-the-counter naloxone sales have been lower, so quarterly results may remain uneven.

What to Watch Next

Key items include the timing of U.S. government orders, trends in naloxone sales, progress on debt reduction and the search for a permanent finance chief. Opening trading Volume will show whether the pre-market decline holds in the regular session.